In cfDNA, the 96-bp amplicon was significantly higher in patients with ER-negative (P=0.004), HER2-negative (P=0.013) and triple-negative status (P=0.004) compared with those whose tumours express ER or HER2. Here, ERBB2 is linked to neoplasm.